Drug for childhood arthritis gets expanded approvals in the EU
A drug that can reduce the risk of flare and disease activity in children with arthritis has been approved based on data from a trial.
Source: labiotech.eu
Ivan Foeldvari News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ivan Foeldvari. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ivan Foeldvari Today - Breaking & Trending Today
Cosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditions
Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) Safety in these pediatric populations was...
Source: pharmiweb.com
EU approves Norvatis' Cosentyx for childhood arthritis
Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions - News - PharmaTimes
Source: pharmatimes.com
Updated Uveitis Recommendations Address Treatment Escalation
The recommendations represent an update of 2018 consensus-based recommendations from the SHARE Initiative and the 2019 American College of Rheumatology/Arthritis Foundation guideline.
Source: medscape.com
Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis ...
Source: pharmiweb.com